Omega-7 oil: a new heart helper?
NCT ID NCT03372733
First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 11 times
Summary
This study looks at whether taking omega-7 oil (palmitoleic acid) can improve cholesterol levels and help control appetite in healthy adults. About 110 participants will take omega-7 capsules daily for 24 weeks and have their blood and health checked. The goal is to see if this natural oil can support heart health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2018
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * Male and female participants 18 years of age or above. * Subject must be healthy, with no known history of cardiovascular disease. * Post-menopausal or women of childbearing potential must be non-lactating and using an effective form of birth control during the course of the study. * Subject understands protocol and provides written, informed consent in addition to a willingness to comply with specified follow-up evaluations. * Subjects with triglyceride levels above 100 mg/dL EXCLUSION CRITERIA: * Pregnancy, planned pregnancy (within the study period), or women currently breastfeeding. * Subjects with allergy or known hypersensitivity to fish, omega-3-acid ethyl esters, omega-7 ethyl esters, other related drugs, or any component of study drugs * Subjects with weight changes greater than 20% over the past 3 months. * Subjects planning a significant change in diet or exercise levels. * Subjects already consuming more than 2 g per day of MUFA, PUFA or other forms of fatty acid supplement if determined by the investigator as having a potential to interfere in the data quality or patient safety. * Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption. * Subjects with any acute and life-threatening condition, such but not limited to as prior sudden cardiac arrest, acute myocardial infarction (last three months), stroke, embolism as per investigator assessment. * Subjects taking supplements or medications that affect lipoproteins for at least the past 8 weeks, such as fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins, Niacin or PCSK9 inhibitors. * Subjects being treated with tamoxifen, estrogens, or progestins that have not been stable for \>4 weeks. * Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion. * Anticipated surgery during the study period. * Liver enzymes (AST or ALT) levels above 3x upper limit of normal. * Blood donation in the last 2 weeks or planned blood donation during the study. * Subjects requiring regular transfusions for any reason. * Subjects may also be excluded for any reason that may compromise their safety or the accuracy of research data or for not complying with protocol directions. * Abnormal baseline laboratory values that are considered not clinically significant by the PI will not exclude the subject.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Can calming inflammation shield the heart?
- Could artery disease drain the body's repair cells?
- Can hidden blood mutations ignite heart disease?
- Could tiny heart vessels hold the key to a common form of heart failure?
- Could an old malaria drug shield hearts in kidney disease?